ACE and chronic kidney disease: Current United States clinical guidelines for managing AS patients with CKD stages 1–4 (eGFR 15–90+ mL/min/1.73 m2) strongly recommend early initiation of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).